CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications
The DOI matches its Crossref record; 256 of the 257 references it cites were found in a registry or an index.
Abstract
Cytochrome P450 (CYP) induction-mediated interaction is one of the major concerns in clinical practice and for the pharmaceutical industry. There are two major issues associated with CYP induction: a reduction in therapeutic efficacy of comedications and an induction in reactive metabolite-induced toxicity. Because CYP induction is a metabolic liability in drug therapy, it is highly desirable to develop new drug candidates that are not potent CYP inducer to avoid the potential of CYP induction-mediated drug interactions. For this reason, today, many drug companies routinely include the assessment of CYP induction at the stage of drug discovery as part of the selection processes of new drug candidates for further clinical development. The purpose of this article is to review the molecular mechanisms of CYP induction and the clinical implications, including pharmacokinetic and pharmacodynamic consequences. In addition, factors that affect the degree of CYP induction and extrapolation of in vitro CYP induction data to in vivo situations will also be discussed. Finally, assessment of the potential of CYP induction at the drug discovery and development stage will be discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 8,209
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Cytochrome P-450: Structure, Mechanism, and Biochemistry
de Montellano, O., & Paul, R. (1986) · Medical Entomology and Zoology · Cited by 2,663
Poland, A., & Knutson, J. C. (1982) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.22.040182.002505 · Cited by 2,515
A physiological approach to hepatic drug clearance
Wilkinson, G. R., & Shand, D. G. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975184377 · Cited by 1,873
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
Poland, A., Glover, E., & Kende, A. S. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33205-2 · Cited by 1,370
Jaeschke, H. (2002) · Toxicological Sciences · doi:10.1093/toxsci/65.2.166 · Cited by 1,304
Gelboin, H. V. (1980) · Physiological Reviews · doi:10.1152/physrev.1980.60.4.1107 · Cited by 1,280
Induction of phase I, II and III drug metabolism/transport by xenobiotics
Xu, C., Li, C. Y.-T., & Kong, A.-N. T. (2005) · Archives of Pharmacal Research · doi:10.1007/bf02977789 · Cited by 1,279
Nebert, D. W., Dalton, T. P., Okey, A. B., & Gonzalez, F. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400004200 · Cited by 1,182
INDUCTION OF CYTOCHROME P4501A1
Whitlock, J. P. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.103 · Cited by 1,124
THE PHARMACOLOGICAL BASIS OF THERAPEUTICS
GOODMAN, L. S., GILMAN, A., & Lasdon, W. S. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196701000-00028 · Cited by 1,018
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
Self-citationSt. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., Serabjit-Singh, C. J., Willson, T. M., Collins, J. L., & Kliewer, S. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130155097 · Cited by 947
SXR, a novel steroid and xenobioticsensing nuclear receptor
Blumberg, B., Sabbagh, W., Juguilon, H., Bolado, J., van Meter, C. M., Ong, E. S., & Evans, R. M. (1998) · Genes & Development · doi:10.1101/gad.12.20.3195 · Cited by 919
Cytochrome P-4502E1: its physiological and pathological role
Lieber, C. S. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.2.517 · Cited by 889
Identification of a human nuclear receptor defines a new signaling pathway for CYP 3 A induction
Bertilsson, G., Heidrich, J., Svensson, K., Åsman, M., Jendeberg, L., Sydow-Bäckman, M., Ohlsson, R., Postlind, H., Blomquist, P., & Berkenstam, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12208 · Cited by 872
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & Forman, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Self-citationMoore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001215200 · Cited by 815
Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 789
The Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity
Watkins, R. E., Wisely, G. B., Moore, L. B., Collins, J. L., Lambert, M. H., Williams, S. P., Willson, T. M., Kliewer, S. A., & Redinbo, M. R. (2001) · Science · doi:10.1126/science.1060762 · Cited by 760
Waxman, D. J. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1351 · Cited by 753
Honkakoski, P., Zelko, I., Sueyoshi, T., & Negishi, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5652 · Cited by 700
Drug Interactions with Tobacco Smoking: An Update
Zevin, S., & Benowitz, N. L. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00004 · Cited by 692
The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution
Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. D., Tomkinson, N. C. O., LeCluyse, E. L., Lambert, M. H., Willson, T. M., et al. (2000) · Molecular Endocrinology · doi:10.1210/me.14.1.27 · Cited by 672
The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene
Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., & Negishi, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6043 · Cited by 668
Humanized xenobiotic response in mice expressing nuclear receptor SXR
Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brunt, E. M., Guzelian, P. S., & Evans, R. M. (2000) · Nature · doi:10.1038/35019116 · Cited by 660
Role of CYP2E1 in the Hepatotoxicity of Acetaminophen
Lee, S. S. T., Buters, J. T. M., Pineau, T., Fernandez-Salguero, P., & Gonzalez, F. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.20.12063 · Cited by 656
The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism
Wei, P., Zhang, J., Egan-Hafley, M., Liang, S., & Moore, D. D. (2000) · Nature · doi:10.1038/35038112 · Cited by 654 · cited 1×
“Although treatment with PB significantly induced Cyp2b10 gene in CAR mice, PB had no inductive effect in CAR mice (38).”
BackgroundEnzyme induction in the cytochrome P-450 system
Okey, A. B. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90030-6 · Cited by 625
Phenobarbital-Responsive Nuclear Translocation of the Receptor CAR in Induction of the CYP2B Gene
Kawamoto, T., Sueyoshi, T., Zelko, I., Moore, R., Washburn, K., & Negishi, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6318 · Cited by 549
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C., & Watkins, P. B. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116064 · Cited by 528
Ekström, G., & Ingelman-Sundberg, M. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90338-9 · Cited by 522
Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Reciprocal activation of Xenobiotic response genes by nuclear receptors SXR/PXR and CAR
Xie, W., Barwick, J. L., Simon, C. M., Pierce, A. M., Safe, S., Blumberg, B., Guzelian, P. S., & Evans, R. M. (2000) · Genes & Development · doi:10.1101/gad.846800 · Cited by 508
de Waziers, I., Cugnenc, P. H., Yang, C. S., Leroux, J. P., & Beaune, P. H. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12474-9 · Cited by 502
Baes, M., Gulick, T., Choi, H. S., Martinoli, M. G., Simha, D., & Moore, D. D. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1544 · Cited by 494
Ritonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents
Hsu, A., Granneman, G. R., & Bertz, R. J. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835040-00002 · Cited by 483
Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2
Raucy, J. L., Lasker, J. M., Lieber, C. S., & Black, M. (1989) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(89)90278-6 · Cited by 478
LeCluyse, E. L. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00135-x · Cited by 477
Androstane metabolites bind to and deactivate the nuclear receptor CAR-β
Forman, B. M., Tzameli, I., Choi, H.-S., Chen, J., Simha, D., Seol, W., Evans, R. M., & Moore, D. D. (1998) · Nature · doi:10.1038/26996 · Cited by 476
Induction of Drug Metabolism: The Role of Nuclear Receptors
Handschin, C., & Meyer, U. A. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.2 · Cited by 470
Denison, M. S., Fisher, J. M., & Whitlock, J. P. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77819-3 · Cited by 451
Luo, G., Cunningham, M., Kim, S., Burn, T., Lin, J., Sinz, M., Hamilton, G., Rizzo, C., Jolley, S., Gilbert, D., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.7.795 · Cited by 442
Self-citationRodríguez-Antona, C., Donato, M. T., Boobis, A., Edwards, R. J., Watts, P. S., Castell, J. V., & Gómez-Lechón, M.-J. (2002) · Xenobiotica · doi:10.1080/00498250210128675 · Cited by 420
Regulation of cytochrome p450 by inflammatory mediators: why and how?
Morgan, E. T. (2001) · PubMed · Cited by 408
Sugatani, J., Kojima, H., Ueda, A., Kakizaki, S., Yoshinari, K., Gong, Q.-H., Owens, I. S., Negishi, M., & Sueyoshi, T. (2001) · Hepatology · doi:10.1053/jhep.2001.24172 · Cited by 381
Regulation of the Human CYP2B6 Gene by the Nuclear Pregnane X Receptor
Goodwin, B., Moore, L. B., Stoltz, C. M., McKee, D. D., & Kliewer, S. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12603-x · Cited by 374
Pascussi, J.-M., Drocourt, L., Fabre, J.-M., Maurel, P., & Vilarem, M.-J. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12072-x · Cited by 372
Phenobarbital Response Elements of Cytochrome P450 Genes and Nuclear Receptors
Sueyoshi, T., & Negishi, M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.123 · Cited by 362
Inhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Wu, C.-Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Rowland, M., Gomez, D. Y., & Wacher, V. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90168-x · Cited by 356
Drocourt, L., Ourlin, J.-C., Pascussi, J.-M., Maurel, P., & Vilarem, M.-J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201323200 · Cited by 356
Clearance approaches in pharmacology.
Wilkinson, G. R. (1987) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06653-0 · Cited by 355
Moore, L. B., Maglich, J. M., McKee, D. D., Wisely, B., Willson, T. M., Kliewer, S. A., Lambert, M. H., & Moore, J. T. (2002) · Molecular Endocrinology · doi:10.1210/me.16.5.977 · Cited by 355
Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation
MANYIKE, P., KHARASCH, E., KALHORN, T., & SLATTERY, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104736 · Cited by 355
Is the Role of the Small Intestine in First-Pass Metabolism Overemphasized?
Lin, J. H., Chiba, M., & Baillie, T. A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01402-9 · Cited by 352
Self-citationInduction of CYP2C genes in human hepatocytes in primary culture.
Gerbal‐Chaloin, S., Pascussi, J., Pichard‐Garcia, L., Daujat‐Chavanieu, M., Waechter, F., Fabre, J.-M., Carrère, N., & Maurel, P. (2001) · PubMed · Cited by 345
Madan, A., Graham, R. A., Carroll, K. M., Mudra, D. R., Burton, L. A., Krueger, L. A., Downey, A. D., Czerwinski, M., Forster, J., Ribadeneira, M. D., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.421 · Cited by 338
Hebert, M. F., Roberts, J. P., Prueksaritanont, T., & Benet, L. Z. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.171 · Cited by 337
Ged, C., Rouillon, J., Pichard, L., Combalbert, J., Bressot, N., Bories, P., Michel, H., Beaune, P., & Maurel, P. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03516.x · Cited by 333 · cited 2×
“rifampicin (600 mg/day) for 4 days (102).”
BackgroundPascussi, J. M., Gerbal-Chaloin, S., Drocourt, L., Maurel, P., & Vilarem, M. J. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00483-x · Cited by 330
Regulation of CYP3A Gene Transcription by the Pregnane X Receptor
Goodwin, B., Redinbo, M. R., & Kliewer, S. A. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.111901.111051 · Cited by 327
Protection against Acetaminophen Toxicity in CYP1A2 and CYP2E1 Double-Null Mice
Zaher, H., Buters, J. T. M., Ward, J. M., Bruno, M. K., Lucas, A. M., Stern, S. T., Cohen, S. D., & Gonzalez, F. J. (1998) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1998.8501 · Cited by 320
Pollenz, R. S., Sattler, C. A., & Poland, A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10014-x · Cited by 312
Drug–drug interaction mediated by inhibition and induction of P-glycoprotein
Lin, J. H. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00171-0 · Cited by 309
Self-citationOmeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450
Diaz, D., Fabrev, I., Daujat, M., Aubert, B. S., Bories, P., Michel, H., & Maurel, P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90963-2 · Cited by 308
Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by Human CYP3A4
Thummel, K. E., Lee, C. A., Kunze, K. L., Nelson, S. D., & Slattery, J. T. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90295-8 · Cited by 296
Zhang, J., Kuehl, P., Green, E. D., Touchman, J. W., Watkins, P. B., Daly, A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00003 · Cited by 292
Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes
Lin, J. H., & Lu, A. Y. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.535 · Cited by 285
Self-citationDifferential Induction of Prehepatic and Hepatic Metabolism of Verapamil by Rifampin
Fromm, M. F., Busse, D., Kroemer, H. K., & Eichelbaum, M. (1996) · Hepatology · doi:10.1002/hep.510240407 · Cited by 283
Differential Transactivation by Two Isoforms of the Orphan Nuclear Hormone Receptor CAR
Choi, H.-S., Chung, M., Tzameli, I., Simha, D., Lee, Y.-K., Seol, W., & Moore, D. D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23565 · Cited by 279
Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes
Wang, H., & LeCluyse, E. L. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00003 · Cited by 278
Song, B. J., Veech, R. L., Park, S. S., Gelboin, H. V., & Gonzalez, F. J. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94103-7 · Cited by 277
Transcriptional Regulation of CYP2C9 Gene
Gerbal-Chaloin, S., Daujat, M., Pascussi, J.-M., Pichard-Garcia, L., Vilarem, M.-J., & Maurel, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107228200 · Cited by 262
Unmasking the dynamic interplay between efflux transporters and metabolic enzymes
Benet, L. Z., Cummins, C. L., & Wu, C. Y. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2002.12.002 · Cited by 256
Transcriptional Regulation of the Human CYP3A4Gene by the Constitutive Androstane Receptor
Goodwin, B., Hodgson, E., D'Costa, D. J., Robertson, G. R., & Liddle, C. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.2.359 · Cited by 254
Pascussi, J.-M., Gerbal-Chaloin, S., Fabre, J.-M., Maurel, P., & Vilarem, M.-J. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12718-6 · Cited by 253
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking*1
FABER, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.003 · Cited by 250
Rifampin drastically reduces plasma concentrations and effects of oral midazolam
Backman, J. T., Olkkola, K. T., & Neuvonen, P. J. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90018-1 · Cited by 242
Dai, Y., Rashba-Step, J., & Cederbaum, A. I. (1993) · Biochemistry · doi:10.1021/bi00078a017 · Cited by 240
Wei, P., Zhang, J., Dowhan, D. H., Han, Y., & Moore, D. D. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500087 · Cited by 240
Stimulatory effect of brussels sprouts and cabbage on human drug metabolism
Pantuck, E. J., Pantuck, C. B., Garland, W. A., Min, B. H., Wattenberg, L. W., Anderson, K. E., Kappas, A., & Conney, A. H. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197925188 · Cited by 239
KHARASCH, E., HOFFER, C., WHITTINGTON, D., & SHEFFELS, P. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.003 · Cited by 238
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
Baldwin, Clarke, & Chenery (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00030.x · Cited by 235
Kocarek, T. A., Schuetz, E. G., Strom, S. C., Fisher, R. A., & Guzelian, P. S. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06553-5 · Cited by 230
Thummel, K. E., Shen, D. D., Podoll, T. D., Kunze, K. L., Trager, W. F., Bacchi, C. E., Marsh, C. L., McVicar, J. P., Barr, D. M., & Perkins, J. D. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22836-1 · Cited by 223
Chang, T. K. H., Yu, L., Maurel, P., & Waxman, D. J. (1997) · PubMed · Cited by 219
Wang, H., Faucette, S., Sueyoshi, T., Moore, R., Ferguson, S., Negishi, M., & LeCluyse, E. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212482200 · Cited by 215
Koop, D. R., Crump, B. L., Nordblom, G. D., & Coon, M. J. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4065 · Cited by 213
(2001) · Wiley eBooks · doi:10.1002/9783906390437 · Cited by 212
Rat Pregnane X Receptor: Molecular Cloning, Tissue Distribution, and Xenobiotic Regulation
Zhang, H., LeCulyse, E., Liu, L., Hu, M., Matoney, L., Zhu, W., & Yan, B. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1307 · Cited by 205
Gorski, J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00187-5 · Cited by 205
Lu, C., & Li, A. P. (2001) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(01)00162-4 · Cited by 203
Stabilization of Cytochrome P450j Messenger Ribonucleic Acid in the Diabetic Rat
Song, B. J., Matsunaga, T., Hardwick, J. P., Park, S. S., Veech, R. L., Yang, C. S., Gelboin, H. V., & Gonzalez, F. J. (1987) · Molecular Endocrinology · doi:10.1210/mend-1-8-542 · Cited by 201
Miller, A. G., Israel, D., & Whitlock, J. P. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32693-0 · Cited by 198
Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes
LeCluyse, E. L., Madan, A., Hamilton, G., Carroll, K., DeHaan, R., & Parkinson, A. (2000) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/(sici)1099-0461(2000)14:4<177::aid-jbt1>3.0.co;2-4 · Cited by 196
LeCluyse, E. L., Bullock, P. L., & Parkinson, A. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00418-8 · Cited by 193
Benet, L., Cummins, C., & Wu, C. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489389 · Cited by 188
Squires, E. J., Sueyoshi, T., & Negishi, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407281200 · Cited by 188
THE HIGH INCIDENCE OF TUBERCULOSIS AMONG RENAL TRANSPLANT RECIPIENTS IN INDIA
Sakhuja, V., Jha, V., Varma, P. P., Joshi, K., & Chugh, K. S. (1996) · Transplantation · doi:10.1097/00007890-199601270-00008 · Cited by 186
Pohjanvirta, R., Wong, J. M. Y., Li, W., Harper, P. A., Tuomisto, J., & Okey, A. B. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.86 · Cited by 184 · cited 1×
“(designated as Ahr) of Han/Wistar rats had a critical point mutation in the first base of intron 10, leading to three splicing variants with deletions and insertions (109).”
BackgroundHuang, S.-M. (2004) · Applications of Pharmacokinetic Principles in Drug Development · doi:10.1007/978-1-4419-9216-1_10 · Cited by 181
Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Maurel, P., & Guzelian, P. S. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84558-1 · Cited by 179
The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.
Holtbecker, N., Fromm, M. F., Kroemer, H. K., Ohnhaus, E. E., & Heidemann, H. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08415-6 · Cited by 178
Polymorphisms in the human AH receptor
Harper, P. A., Wong, J. M. Y., Lam, M. S. M., & Okey, A. B. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00071-6 · Cited by 168
Maurel, P. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00417-6 · Cited by 167
Ju, C., & Uetrecht, J. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337333 · Cited by 166
Sugatani, J., Nishitani, S., Yamakawa, K., Yoshinari, K., Sueyoshi, T., Negishi, M., & Miwa, M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.007161 · Cited by 165
Glimepiride: A Review of its Use in the Management of Type 2 Diabetes Mellitus
Langtry, H. D., & Balfour, J. A. (1998) · Drugs · doi:10.2165/00003495-199855040-00007 · Cited by 164
Armstrong, S. C., & Cozza, K. L. (2003) · Psychosomatics · doi:10.1176/appi.psy.44.2.167 · Cited by 164
Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors
Morimoto, M., Hagbjörk, A.-L., Wan, Y.-J. Y., Fu, P. C., Clot, P., Albano, E., Ingelman-Sundberg, M., & French, S. W. (1995) · Hepatology · doi:10.1002/hep.1840210620 · Cited by 163
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
McCune, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110215 · Cited by 162
Trottier, E., Belzil, A., Stoltz, C., & Anderson, A. (1995) · Gene · doi:10.1016/0378-1119(94)00916-g · Cited by 160
Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms
Smart, J., & Daly, A. K. (2000) · Pharmacogenetics · doi:10.1097/00008571-200002000-00003 · Cited by 155
Conney, A. H. (2003) · PubMed · Cited by 154
Drug Interactions of HIV Protease Inhibitors
Malaty, L. I., & Kuper, J. J. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00005 · Cited by 154
Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans
Zand, R., Nelson, S. D., Slattery, J. T., Thummel, K. E., Kalhorn, T. F., Adams, S. P., & Wright, J. M. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.125 · Cited by 153
Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells
Li, W., Harper, P. A., Tang, B.-K., & Okey, A. B. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00208-1 · Cited by 149
The carcinogenicity of environmental tobacco smoke
Witschi, H. R., Espiritu, I., Peake, J. L., Wu, K., Maronpot, R. R., & Pinkerton, K. E. (1997) · Carcinogenesis · doi:10.1093/carcin/18.3.575 · Cited by 149
Zelko, I., Sueyoshi, T., Kawamoto, T., Moore, R., & Negishi, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.8.2838-2846.2001 · Cited by 149
Kall, M. A., Vang, O., & Clausen, J. (1996) · Carcinogenesis · doi:10.1093/carcin/17.4.793 · Cited by 149
LeCluyse, E. L., Bullock, P. L., Parkinson, A., & Hochman, J. H. (1996) · Pharmaceutical biotechnology · doi:10.1007/978-1-4899-1863-5_9 · Cited by 147
(1999) · CRC Press eBooks · doi:10.1201/b13995 · Cited by 147
Expression and Induction of CYP2C P450 Enzymes in Primary Cultures of Human Hepatocytes
Raucy, J. L., Mueller, L., Duan, K., Allen, S. W., Strom, S. C., & Lasker, J. M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033837 · Cited by 146
Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers
Hebert, M. F., Fisher, R. M., Marsh, C. L., Dressler, D., & Bekersky, I. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007499 · Cited by 143
Rashbastep, J., Turro, N., & Cederbaum, A. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1054 · Cited by 142
The Use of Human Hepatocyte Cultures to Study the Induction of Cytochrome P-450
Kostrubsky, V. E., Ramachandran, V., Venkataramanan, R., Dorko, K., Esplen, J. E., Zhang, S., Sinclair, J. F., Wrighton, S. A., & Strom, S. C. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15238-5 · Cited by 141
Pharmaceutical profiling in drug discovery for lead selection
Borchardt, R. T. (2004) · Cited by 139
Screening for the potential of a drug candidate to cause idiosyncratic drug reactions
Uetrecht, J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02816-2 · Cited by 139
Codeine O‐demethylation co‐segregates with polymorphic debrisoquine hydroxylation.
Yue, Q.-Y., Svensson, J., Alm, C., Sjöqvist, F., & Säwe, J. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03556.x · Cited by 139
Differential expression and function of CYP2C isoforms in human intestine and liver
L??pple, F., von Richter, O., Fromm, M. F., Richter, T., Thon, K. P., Wisser, H., Griese, E.-U., Eichelbaum, M., & Kivist??, K. T. (2003) · Pharmacogenetics · doi:10.1097/00008571-200309000-00005 · Cited by 136
Barwick, J. L., Quattrochi, L. C., Mills, A. S., Potenza, C., Tukey, R. H., & Guzelian, P. S. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09115-1 · Cited by 134
Rost, K. L., Brösicke, H., Brockmöller, J., Scheffler, M., Helge, H., & Roots, I. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.126 · Cited by 132
Yue, Q.-Y., Hasselström, J., Svensson, J., & Säwe, J. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05585.x · Cited by 130
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide
Niemi, M., Backman, J. T., Neuvonen, M., Neuvonen, P. J., & Kivistö, K. T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115822 · Cited by 130
Poland, A., & Glover, E. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09468-4 · Cited by 129
Armstrong, S. C., & Cozza, K. L. (2003) · Psychosomatics · doi:10.1176/appi.psy.44.6.515 · Cited by 128
Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract
McDonnell, W. M., Scheiman, J. M., & Traber, P. G. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91171-y · Cited by 122
OKEY, A., FRANC, M., MOFFAT, I., TIJET, N., BOUTROS, P., KORKALAINEN, M., TUOMISTO, J., & POHJANVIRTA, R. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.12.028 · Cited by 122
Characterization of Phenobarbital-inducible Mouse Cyp2b10 Gene Transcription in Primary Hepatocytes
Honkakoski, P., Moore, R., Gynther, J., & Negishi, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.16.9746 · Cited by 118
Koyano, S., Kurose, K., Saito, Y., Ozawa, S., Hasegawa, R., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Nakajima, T., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.1.149 · Cited by 114
Role of CYP1A2 in the Hepatotoxicity of Acetaminophen: Investigations UsingCyp1a2Null Mice
Tonge, R. P., Kelly, E. J., Bruschi, S. A., Kalhorn, T. F., Eaton, D. L., Nebert, D. W., & Nelson, S. D. (1998) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1998.8543 · Cited by 113
Kleinbloesem, C. H., van Harten, J., Wilson, J. H. P., Danhof, M., van Brummelen, P., & Breimer, D. D. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.134 · Cited by 113
The mechanism of the warfarin-rifampin drug interaction in humans
Heimark, L. D., Gibaldi, M., Trager, W. F., O'Reilly, R. A., & Goulart, D. A. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.168 · Cited by 112
Enhanced Acetaminophen Toxicity by Activation of the Pregnane X Receptor
Guo, G. L. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh286 · Cited by 112
Loss of analgesic effect of morphine due to coadministration of rifampin
Fromm, M. F., Eckhardt, K., Li, S., Schänzle, G., Hofmann, U., Mikus, G., & Eichelbaum, M. F. (1997) · Pain · doi:10.1016/s0304-3959(97)00044-4 · Cited by 110
Schuetz, E. G., Schmid, W., Schütz, G., Brimer, C., Yasuda, K., Kamataki, T., Bornheim, L. M., Myles, K., & Cole, T. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15361-5 · Cited by 109
Polymorphisms of human Ah receptor gene are not involved in lung cancer
Kawajiri, K., Watanabe, J., Eguchi, H., Nakachi, K., Kiyohara, C., & Hayashi, S.-I. (1995) · Pharmacogenetics · doi:10.1097/00008571-199506000-00003 · Cited by 108
Sugatani, J., Yamakawa, K., Tonda, E., Nishitani, S., Yoshinari, K., Degawa, M., Abe, I., Noguchi, H., & Miwa, M. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.11.002 · Cited by 107
Dvořák, Z., Modrianský, M., Pichard‐Garcia, L., Balaguer, P., Vilarem, M., Ulrichová, J., Maurel, P., & Pascussi, J. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.1.160 · Cited by 107
Orphan Receptor Promiscuity in the Induction of Cytochromes P450 by Xenobiotics
Smirlis, D., Muangmoonchai, R., Edwards, M., Phillips, I. R., & Shephard, E. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005930200 · Cited by 107
Hon-Wing, L., Paustenbach, D. J., Murray, F. J., & Andersen, M. E. (1990) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(90)90313-j · Cited by 106
Triazolam is ineffective in patients taking rifampin
Villikka, K., Kivistö, K. T., Backman, J. T., Olkkola, K. T., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90176-4 · Cited by 106
Effects of smoking cessation and reduction in asthmatics
Tønnesen, P., Pisinger, C., Hvidberg, S., Wennike, P., Bremann, L., Westin, Å., Thomsen, C., & Nilsson, F. (2005) · Nicotine & Tobacco Research · doi:10.1080/14622200412331328411 · Cited by 105
Drocourt, L., Pascussi, J., Assénat, E., Fabre, J.-M., Maurel, P., & Vilarem, M. (2001) · PubMed · Cited by 104
Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers.
El-Sankary, W., Gibson, G. G., Ayrton, A. D., & Plant, N. J. (2001) · PubMed · Cited by 103
Effect of Rifampin on the Pharmacokinetics of Rosiglitazone in Healthy Subjects
Park, J. Y., Kim, K., Kang, M., Kim, S., & Shin, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.003 · Cited by 102
HONKAKOSKI, P., & NEGISHI, M. (1998) · Biochemical Journal · doi:10.1042/bj3300889 · Cited by 100
The complex interaction between ethanol and acetaminophen*
Slattery, J. T., Nelson, S. D., & Thummel, K. E. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90050-8 · Cited by 99
Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes
Sahi, J., Hamilton, G., Sinz, M., Barros, S., Huang, S.-M., Lesko, L. J., & LeCluyse, E. L. (2000) · Xenobiotica · doi:10.1080/004982500237668 · Cited by 99
The enantioselective glucuronidation of morphine in rats and humans
Coughtrie, M. W. H., Ask, B., Rane, A., Burchell, B., & Hume, R. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90625-4 · Cited by 97
Xu, L., Li, A. P., Kaminski, D. L., & Ruh, M. F. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00149-0 · Cited by 97
Renal Allograft Dysfunction Associated with Rifampin–Tacrolimus Interaction
Chenhsu, R.-Y., Loong, C.-C., Chou, M.-H., Lin, M.-F., & Yang, W.-C. (2000) · The Annals of Pharmacotherapy · doi:10.1345/1542-6270(2000)034<0027:radawr>2.3.co;2 · Cited by 96
Pharmacokinetic Factors in the Modern Drug Treatment of Tuberculosis
Douglas, J. G., & McLeod, M. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937020-00003 · Cited by 95
Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes
Glaeser, H., Drescher, S., Eichelbaum, M. F., & Fromm, M. F. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02265.x · Cited by 94
Diliberto, J. J., Akubue, P. I., Luebke, R. W., & Birnbaum, L. S. (1995) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1995.1025 · Cited by 94
Regulation of Drug and Bile Salt Transporters in Liver and Intestine
Kullak-Ublick, G. A., & Becker, M.-B. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120026398 · Cited by 93
Birnbaum, L. S., McDonald, M. M., Blair, P. C., Clark, A. M., & Harris, M. W. (1990) · Fundamental and Applied Toxicology · doi:10.1016/0272-0590(90)90175-j · Cited by 91
Tang, C., Lin, J. H., & Lu, A. Y. H. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003236 · Cited by 89
Self-citationRefinement of an in vitro cell model for cytochrome P450 induction.
Silva, J. M., Morin, P.-E., Day, S. H., Kennedy, B. P., Payette, P., Rushmore, T. H., Yergey, J. A., & Nicoll‐Griffith, D. A. (1998) · PubMed · Cited by 88
Hon-Wing, L., Ku, R. H., Paustenbach, D. J., & Andersen, M. E. (1988) · Toxicology Letters · doi:10.1016/0378-4274(88)90098-7 · Cited by 86
The effect of antipyrine and rifampin on the metabolism of diazepam
Ohnhaus, E. E., Brockmeyer, N. H., Dylewicz, P., & Habicht, H. (1987) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1987.125 · Cited by 86
Effect of Cryopreservation on Cytochrome P-450 Enzyme Induction in Cultured Rat Hepatocytes
Madan, A., DeHaan, R., Mudra, D., Carroll, K., LeCluyse, E., & Parkinson, A. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14907-0 · Cited by 85
Specific and Dose–Dependent Enzyme Induction by Omeprazole in Human Beings
Rost, K. L., Brösicke, H., Heinemeyer, G., & Roots, I. (1994) · Hepatology · doi:10.1002/hep.1840200516 · Cited by 85
Influence of Type of Cigarette on Peripheral versus Central Lung Cancer
Brooks, D. R., Austin, J. H. M., Heelan, R. T., Ginsberg, M. S., Shin, V., Olson, S. H., Muscat, J. E., & Stellman, S. D. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0468 · Cited by 84
Wang, H., Faucette, S. R., Gilbert, D., Jolley, S. L., Sueyoshi, T., Negishi, M., & LeCluyse, E. L. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.620 · Cited by 84
Yoshinari, K., Sueyoshi, T., Moore, R., & Negishi, M. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.2.278 · Cited by 84
Lin, J. H., Chiba, M., Chen, I., et al. (1999) · PubMed · Cited by 83
Self-citationQuinidine-Rifampin Interaction
Twum-Barima, Y., & Carruthers, S. G. (1981) · New England Journal of Medicine · doi:10.1056/nejm198106113042405 · Cited by 82
Mechanism of dioxin action: Ah receptor-mediated increase in promoter accessibility in vivo.
Wu, L., & Whitlock, J. P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4811 · Cited by 81
Grub, S., Bryson, H., Goggin, T., Lüdin, E., & Jorga, K. M. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100277 · Cited by 81
Jinno, H., Tanaka‐Kagawa, T., Hanioka, N., Ishida, S., Saeki, M., Soyama, A., Itoda, M., Nishimura, T., Saito, Y., Ozawa, S., et al. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.496 · Cited by 81
Huss, J. M., & Kasper, C. B. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.1.48 · Cited by 81
Modry, D. L., Stinson, E. B., DYER, P. E., Jamieson, S. W., Baldwin, J. C., & Shumway, N. E. (1985) · Transplantation · doi:10.1097/00007890-198503000-00022 · Cited by 80
Sesardic, D., Cole, K. J., Edwards, R. J., Davies, D. S., Thomas, P. E., Levin, W., & Boobis, A. R. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90056-q · Cited by 77
Induction of Cytochrome P4503A by Taxol in Primary Cultures of Human Hepatocytes
Kostrubsky, V. E., Lewis, L. D., Strom, S. C., Wood, S. G., Schuetz, E. G., Schuetz, J. D., Sinclair, P. R., Wrighton, S. A., & Sinclair, J. F. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0730 · Cited by 76
Parkinson, A., Thomas, P. E., Ryan, D. E., Reik, L. M., Safe, S. H., Robertson, L. W., & Levin, W. (1983) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(83)90024-3 · Cited by 76
Interaction of Chronic Daily Warfarin Therapy and Rifampin
O’Reilly, R. A. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-506 · Cited by 75
Sarich, T. C., Kalhorn, T. F., Magee, S., Alsayegh, F., Adams, S., Slattery, J. T., Goldstein, J. A., Nelson, S. D., & Wright, J. M. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90148-x · Cited by 75
Human Aryl Hydrocarbon Receptor Polymorphisms That Result in Loss of CYP1A1 Induction
Wong, J. M. Y., Okey, A. B., & Harper, P. A. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5861 · Cited by 73
Nallani, S. C., Glauser, T. A., Hariparsad, N., Setchell, K., Buckley, D. J., Buckley, A. R., & Desai, P. B. (2003) · Epilepsia · doi:10.1111/j.0013-9580.2003.06203.x · Cited by 73
TUBERCULOSIS IN RENAL TRANSPLANT RECIPIENTS1
Sayıner, A., Ece, T., Duman, S., Yıldız, A., zkahya, M., aslan, Z. K., & Tokat, Y. (1999) · Transplantation · doi:10.1097/00007890-199911150-00009 · Cited by 73
Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine
Schmider, J., Brockmöller, J., Arold, G., Bauer, S., & Roots, I. (1999) · Pharmacogenetics and Genomics · doi:10.1097/01213011-199912000-00007 · Cited by 72
Cauchi, S., Stücker, I., Solas, C., Laurent-Puig, P., Cénée, S., Hémon, D., Jacquet, M., Kremers, P., Beaune, P., & Massaad-Massade, L. (2001) · Carcinogenesis · doi:10.1093/carcin/22.11.1819 · Cited by 72
Warfarin Metabolism and Drug-Drug Interactions
O’Reilly, R. A. (1987) · Springer eBooks · doi:10.1007/978-1-4757-5985-3_18 · Cited by 71
Microsomal generation of reactive oxygen species and their possible role in alcohol hepatotoxicity.
Cederbaum, A. I. (1991) · PubMed · Cited by 71
Research works printed but not linked: 27
- H. V. Gelboin, 1980, Pharmacol. Rev., 60, 1107
- J. M. Silva, 1998, Drug Metab. Dispos., 26, 490
- W. El-Sankary, 2001, Drug Metab. Dispos., 29, 1499
- R. C. Pollenz, 1994, Mol. Pharmacol., 45, 428
- J.-M. Passcussi, 2000, Mol. Pharmacol., 58, 1441, 10.1124/mol.58.6.1441 · doi:10.1124/mol.58.6.1441 · Paper page
- T. A. Kocarek, 1995, Drug Metab. Dispos., 23, 415
- S. M. Fontaine, 2001, Drug Metab. Dispos., 29, 1236
- J. L. Barwick, 1996, Mol. Pharmacol., 50, 10
- T. Shimada, 1994, J. Pharmacol. Exp. Ther., 270, 414
- K. E. Thummel, 1994, J. Pharmacol. Exp. Ther., 271, 557
- M. F. Paine, 1997, J. Pharmacol. Exp. Ther., 283, 1552
- E. T. Morgan, 2001, Drug Metab. Dispos., 29, 207
- T. K. Chang, 1997, Cancer Res., 57, 1946
- A. Poland, 1990, Mol. Pharmacol., 38, 306
- G. R. Wilkinson, 1987, Pharmacol. Rev., 39, 1
- N. Holtbecker, 1996, Drug Metab. Dispos., 24, 1121
- S. Gerbal-Chaloin, 2001, Drug Metab. Dispos., 29, 242
- L. Drocourt, 2001, Drug Metab. Dispos., 29, 1325
- S. C. Nallami, 2003, Epilepsia, 44, 1428
- I. Waziers de, 1990, J. Pharmacol. Exp. Ther., 253, 387
- R. A. O'Reilly, 1987, Adv. Exp. Med. Biol., 214, 205
- Y. Caraco, 1997, J. Pharmacol. Exp. Ther., 281, 330
- W. D. Fiske, D. Mayers, and K. Wagner. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals [abstract no. 568]. 4th Conference on Retroviruses and Opportunistic Infections. 1996, Jan 28–Feb 1. Washington, DC.
- A. H. Conney, 2003, Cancer Res., 63, 7005
- A. Cantani, 2005, Eur. Rev. Med. Pharmacol. Sci., 9, 23
- M. Morimoto, 1995, Hepatology, 21, 1610
- E. L. LeCluyse, 1996, Model Systems for Biopharmaceutical Assessment of Drug Absorption and Metabolism, 125
Cited by
A liver-on-a-chip platform with bioprinted hepatic spheroids
Bhise, N. S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M., Lang, Q., Shrike Zhang, Y., Shin, S. R., Calzone, G., et al. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/014101 · Cited by 615
Obach, R. S., Walsky, R. L., & Venkatakrishnan, K. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012633 · Cited by 460
The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group
Koziolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M., Hens, B., Hoad, C. L., Jedamzik, P., Madla, C. M., Maliepaard, M., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.003 · Cited by 385
Organotypic liver culture models: meeting current challenges in toxicity testing
LeCluyse, E. L., Witek, R. P., Andersen, M. E., & Powers, M. J. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.682115 · Cited by 363
Predicting Drug-Target Interaction Networks Based on Functional Groups and Biological Features
He, Z., Zhang, J., Shi, X.-H., Hu, L.-L., Kong, X., Cai, Y.-D., & Chou, K.-C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009603 · Cited by 288
Metadata
- Authors
- Lin, J. H.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lin, Jiunn H.
- ORCID
- Lin, Jiunn H.
- Venue
- Pharmaceutical Research
- Published
- 2006-05-26
- Volume
- 23
- Issue
- 6
- Pages
- 1089-1116
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1997271604
- Cited by
- 264
- References
- 257
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 7 · 2023: 3 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 11 · 2015: 13 · 2014: 11 · 2013: 15 · 2012: 22
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- cytochrome P450 induction, drug interactions, CYP inducers, in vitro-in vivo extrapolation, pharmacokinetics, pharmacodynamics, drug discovery, drug development, treatment efficacy
- MeSH terms
- Pregnane X Receptor, Constitutive Androstane Receptor, Animals, Drug Interactions, Enzyme Induction, Humans, Liver, Pharmacokinetics, Pharmacology, Receptors, Steroid, Species Specificity, Transcription Factors, Genetic Variation, Drug Design, Receptors, Cytoplasmic and Nuclear, Receptors, Aryl Hydrocarbon, Cytochrome P-450 CYP2B1, Cytochrome P-450 CYP2E1, Receptor Cross-Talk, Cytochrome P-450 CYP3A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.